EBITDA: Income before interest, taxes, depreciation and amortization.
Seres Therapeutics, Inc. (MCRB) had EBITDA of $-89.84M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.79M |
|
$5.70M |
|
-- |
|
$0.79M |
|
$94.76M |
|
$-93.97M |
|
$99.67M |
|
$5.70M |
|
$5.70M |
|
$5.70M |
|
$5.70M |
|
$5.70M |
|
$5.70M |
|
$-93.97M |
|
|
EBITDA |
$-89.84M |
8.86M |
|
8.87M |
|
$0.64 |
|
$0.64 |
|
| Balance Sheet Financials | |
$49.38M |
|
$7.63M |
|
$88.82M |
|
$138.19M |
|
$19.32M |
|
-- |
|
$74.65M |
|
$93.97M |
|
$44.22M |
|
$44.22M |
|
$44.22M |
|
9.56M |
|
| Cash Flow Statement Financials | |
$1.12M |
|
$-0.04M |
|
$13.90M |
|
$39.46M |
|
$54.43M |
|
$14.97M |
|
$10.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-11910.14% |
|
-11910.14% |
|
-11386.31% |
|
721.93% |
|
721.93% |
|
$1.07M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.53 |
|
239.17 |
|
12.88% |
|
12.88% |
|
4.12% |
|
12.88% |
|
$4.63 |
|
$0.12 |
|
$0.13 |
|